Dosing and administration information for SARCLISA + Pd1

Recommended dosage1

Pre-medication should be administered 15 to 60 minutes prior to infusion of SARCLISA

Infusion rates can increase over time, with a 75-minute infusion possible from the 3rd infusion onwards1

Incremental escalation of the infusion rate should be considered only in the absence of infusion-related reactions.1

In patients who experience grade 2 (moderate) infusion-related reactions, a temporary interruption in the infusion should be considered and additional symptomatic medicinal products can be administered.§ After improvement to grade ≤1 (mild), SARCLISA infusion may be resumed at half of the initial infusion rate under close monitoring and supportive care, as needed. If symptoms do not resolve rapidly or do not improve to grade ≤1 after interruption of SARCLISA infusion, persist or worsen despite appropriate medicinal products, or require hospitalisation or are life-threatening, treatment with SARCLISA should be permanently discontinued and additional supportive therapy should be administered, as needed.1

You are now leaving the website.

By clicking on this link, you will be leaving this Sanofi hosted website, and, depending on the link, will be redirected to either another Sanofi website (for example, to view the Sanofi Privacy Policy) or an independent third-party website.
Sanofi has no control over the content or availability of third-party sites or resources that are linked to, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. The existence of a link between this website and any third party site or resource in no way implies that Sanofi in any way approves of the content of these sites or resources, or any use to which such content maybe put.

Please ensure that you read the legal and privacy policy sections of any website to which you link.